Ankylosing spondylitis. Not just another pain in the back

Canadian Family Physician

Volumn 50, Issue FEB., 2004, Pages 257-262

  Maksymowych, Walter P ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID DERIVATIVE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ETANERCEPT; INFLIXIMAB; KETOPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANKYLOSING SPONDYLITIS; BACKACHE; CIRCADIAN RHYTHM; CLINICAL STUDY; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; HUMAN; MORNING STIFFNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIS RADIOGRAPHY; PHYSICAL DISABILITY; PHYSICAL EXAMINATION; RANDOMIZATION; REVIEW; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; TREATMENT FAILURE;

ADULT; ALGORITHMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 1342287406     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Feldtkeller E, Bruckel J, Khan MA. Scientific contributions of ankylosing spondylitis patient advocacy groups. Curr Opin Rheumatol 2000;12:239-47.
2. Gran TJ, Husby G. The epidemiology of ankylosing spondylitis. Semin Arthritis Rheum 1993;22:319-34.
3. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for anklosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
4. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al, and the European Spondyloarthropathy Study Group. The European Spondyloarthropathy Study Group preliminary criteria for the classification of spondyloarthropathy. Arthritis Rheum 1991;34:1218-27.
5. Mau W, Zeidler H, Mau R, Majewski A, Freyschmidt J, Stangel W, et al. Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year follow up. J Rheumatol 1988;7:1109-14.
6. Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, et al. Prevalence of spondyloarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998;41:58-67.
7. Underwood MR, Dawes P. Inflammatory back pain in primary care. Br J Rheumatol 1995;34:1074-7.
8. Calin A, Porta A, Fries JF. Clinical history as screening in ankylosing spondylitis. JAMA 1977;237:2613-4.
9. Amor B, Dougados M, Listrat V, Menkes CJ, Dubost JJ, Roux H, et al. Evaluation de critères de spondylarthropathies d'Amor et de l'European Spondylarthropathy Study Group (ESSG). Une etude transversale de 2228 patients. Ann Med Interne (Paris) 1991;142:85-9.
10. Russell AS, Maksymowych WP, Le Clercq S. Clinical examination of the sacroiliac joints: a prospective study. Arthritis Rheum 1981;24:1575-7.
11. Battafarano DF, West SG, Rak KM, Fortenbery EJ, Chantelois AE. Comparison of bone scan, computed tomography, and magnetic resonance imaging in the diagnosis of active sacroiliitis. Semin Arthritis Rheum 1993;23:161-76.
12. Zink A, Braun J, Listing J, Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis - results from the German rheumatological database. J Rheumatol 2000;27:613-22.
13. Ward MM. Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis Rheum 2002;46:223-31.
14. Dougados M, Behier JM, Jolcine I, Calin A, van der Heijde D, Olivieri I, et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled studt with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 2001;44:180-5.
15. Maksymowych WP. Novel therapies in the treatment of spondyloarthritis. Expert Opin Invest Drugs 2002;11:937-46.
16. Dougados M, van der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E, et al. Sulfasalazine in the treatment of spondyloarthropathy. Arthritis Rheum 1995;38:618-27.
17. Clegg DO, Reda DJ, Weisman Mh, Blackburn WD, Cush JJ, Cannon GW, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2004-12.
18. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
19. Van den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum 2002;46:755-65.
20. German JD, Sack KE, Davis JC. A randomized, double-blind, placebo-controlled trial of etanercept in the treatment of ankylosing spondylitis. N Engl J Med 2002;346:1349-56.
21. Makysmowych WP, Inman RD, Gladman D, Thomson G, Stone M, Karsh J, et al. Canadian Rheumatology Association consensus on the use of anti-TNFα directed therapies in the treatment of spondyloarthritis. J Rheumatol 2003;30:1356-63.